December 8, 2023
MSD’s PD-1 inhibitor Keytruda (pembrolizumab) was the best-selling medicine in Japan in November, after snatching the pole position from Ono Pharmaceutical’s archrival Opdivo (nivolumab) the previous month, according to a monthly snapshot report released by Encise. Keytruda hauled in sales...read more